Literature DB >> 26303045

Exploiting AT2R to Improve CD117 Stem Cell Function In Vitro and In Vivo--Perspectives for Cardiac Stem Cell Therapy.

Marion Ludwig1, Anita Tölk, Anna Skorska, Christian Maschmeier, Ralf Gaebel, Cornelia Aquilina Lux, Gustav Steinhoff, Robert David.   

Abstract

BACKGROUND/AIMS: CD117(+) stem cell (SC) based therapy is considered an alternative therapeutic option for terminal heart disease. However, controversies exist on the effects of CD117(+) SC implantation. In particular, the link between CD117(+) SC function and angiotensin-II-type-2 receptor (AT2R) after MI is continuously discussed. We therefore asked whether 1) AT2R stimulation influences CD117(+) SC properties in vitro and, 2) which effects can be ascribed to AT2R stimulation in vivo.
METHODS: We approached AT2R stimulation with Angiotensin II while simultaneously blocking its opponent receptor AT1 with Losartan. CD117 effects were dissected using a 2D-Matrigel assay and HL-1 co-culture in vitro. A model of myocardial infarction, in which we implanted EGFP(+) CD117 SC, was further applied.
RESULTS: While we found indications for AT2R driven vasculogenesis in vitro, co-culture experiments revealed that CD117(+) SC improve vitality of cardiomyocytes independently of AT2R function. Likewise, untreated CD117(+) SC had a positive effect on cardiac function and acted cardioprotective in vivo.
CONCLUSIONS: Therefore, our data show that transient AT2R stimulation does not significantly add to the beneficial actions of CD117(+) SC in vivo. Yet, exploiting AT2R driven vasculogenis via an optimized AT2R stimulation protocol may become a promising tool for cardiac SC therapy.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26303045     DOI: 10.1159/000430335

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  2 in total

Review 1.  Angiotensin II Type 2 Receptor: A Target for Protection Against Hypertension, Metabolic Dysfunction, and Organ Remodeling.

Authors:  Naureen Fatima; Sanket N Patel; Tahir Hussain
Journal:  Hypertension       Date:  2021-04-12       Impact factor: 10.190

2.  CD271+ Human Mesenchymal Stem Cells Show Antiarrhythmic Effects in a Novel Murine Infarction Model.

Authors:  Haval Sadraddin; Ralf Gaebel; Anna Skorska; Cornelia Aquilina Lux; Sarah Sasse; Beschan Ahmad; Praveen Vasudevan; Gustav Steinhoff; Robert David
Journal:  Cells       Date:  2019-11-20       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.